R
Ridhi Gupta
Researcher at Stanford University
Publications - 21
Citations - 541
Ridhi Gupta is an academic researcher from Stanford University. The author has contributed to research in topics: GiST & Daratumumab. The author has an hindex of 7, co-authored 21 publications receiving 328 citations. Previous affiliations of Ridhi Gupta include Medical University of South Carolina & New York Medical College.
Papers
More filters
Journal ArticleDOI
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H. Gandhi,Robert F. Cornell,Arjun Lakshman,Zhubin Gahvari,Elizabeth McGehee,Megan Jagosky,Ridhi Gupta,William Varnado,Mark A. Fiala,Saurabh Chhabra,Ehsan Malek,Joshua Mansour,Barry Paul,Alyssa Barnstead,Saranya Kodali,Amarendra K. Neppalli,Michaela Liedtke,Swapna Narayana,Kelly N. Godby,Yubin Kang,Ankit Kansagra,Elvira Umyarova,Emma C. Scott,Parameswaran Hari,Ravi Vij,Saad Z. Usmani,Natalie S. Callander,Shaji Kumar,Luciano J. Costa +28 more
TL;DR: Patients with MM refractory to CD38 MoAB have poor prognosis and this study provides benchmark for new therapies to be tested in this population.
Journal ArticleDOI
Current management and prognostic features for gastrointestinal stromal tumor (GIST).
TL;DR: This comprehensive review of the epidemiology, clinical features and diagnostic modalities for GIST is discussed and treatment options for early stage, locally advanced and metastatic GIST are described.
Journal ArticleDOI
Recent advances and novel agents for gastrointestinal stromal tumor (GIST)
TL;DR: GIST research and clinical care now represent a paradigm of translating discoveries in the molecular pathogenesis of cancer into highly effective targeted therapies that selectively inhibit etiologic “driver” pathways, leading to dramatically improved clinical outcomes.
Journal ArticleDOI
Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review
Yazan Migdady,Asiri Ediriwickrema,Ryan P. Jackson,Wendy Kadi,Ridhi Gupta,Francisco Socola,Sally Arai,Beth A. Martin +7 more
TL;DR: A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations, and a short course of daratumumab is a novel treatment after failure of standard treatment options.
Journal ArticleDOI
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Robert F. Cornell,Parameswaran Hari,Shijie Tang,Noa Biran,Natalie S. Callander,Ajai Chari,Saurabh Chhabra,Mark A. Fiala,Zhubin Gahvari,Ujjawal H. Gandhi,Kelly N. Godby,Ridhi Gupta,Sundar Jagannath,Megan Jagosky,Yubin Kang,Ankit Kansagra,Michael Kauffman,Saranya Kodali,Shaji Kumar,Arjun Lakshman,Michaela Liedtke,Sagar Lonial,Xiwen Ma,Ehsan Malek,Joshua Mansour,Joshua Mansour,Elizabeth McGehee,Amarendra K. Neppalli,Barry Paul,Paul G. Richardson,Emma C. Scott,Sharon Shacham,Jatin P. Shah,David S. Siegel,Elvira Umyarova,Saad Z. Usmani,William Varnado,Ravi Vij,Luciano J. Costa +38 more
TL;DR: A ten year review of the sickle cell program in Muhimbili National Hospital, Tanzania and the World Health Organization and Health Action International's Measuring Medicine Price, Availability, Affordability and Price Component.